Phase 2 Spinal Muscular Atrophy Trial, Recruiting NCT06421831 Sponsor: GeneCradle Inc Condition: Spinal Muscular Atrophy
Back to Spinal Muscular Atrophy

Phase 2 Spinal Muscular Atrophy Trial, Recruiting

NCT06421831
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 2 years of age or older at the time of signing the consent form
  • You must have a confirmed genetic and clinical diagnosis of Type 3 Spinal Muscular Atrophy (SMA), caused by a specific gene change on chromosome 5
  • Your score on a standard motor skills test (called the HFMSE) must fall between 10 and 54 at the initial check-up
  • Female participants who are pregnant, breastfeeding, or could become pregnant, as well as all other participants (male and female), must use effective birth control for 6 months after treatment
  • You (or your legal guardian) must be able to understand what the study involves and willingly sign and date a consent form before any study procedures begin

Who may not be able to join:

  • You have previously taken part in any gene therapy research trial
  • You have a high level of a certain antibody (called AAV9 neutralizing antibody) in your blood, at a level of 1:200 or higher (confirm with trial site)
  • You have taken the SMA medication Nusinersen within the last 120 days, or Risdiplam within the last 15 days before treatment
  • You currently need a breathing machine or ventilator support for an average of 16 or more hours per day
  • Your genetic test shows more than 4 copies of the SMN2 gene
  • You require a feeding tube through the nose or stomach to eat
  • You have tested positive for HIV, Hepatitis B, Hepatitis C, or syphilis
  • You have a known allergy or bad reaction to prednisolone, other steroid medications, or their ingredients
  • You have severe joint stiffness or tightening that would prevent you from completing movement tests or receiving the treatment by injection into the spine
  • You have other serious health conditions affecting the heart, brain, blood vessels, digestive system, kidneys, hormones, blood, immune system, or nervous system (including conditions like epilepsy, meningitis, seizures, or mental illness)
  • You have a previous injury (such as a broken bone) or have had surgery that has not yet fully healed or stabilised
  • You have received any vaccine within 2 weeks before treatment
  • The trial doctor believes, for any other reason, that the trial would not be suitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8613501380583

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
GeneCradle Inc
Registry
ClinicalTrials.gov
Start date
10 May 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Treatment-Emergent Adverse Events; Change from baseline on Hammersmith Functional Motor Scale - Expanded (HFMSE) scores at Month 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov